Every Form 4 that Evolent Health, Inc (EVH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow EVH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EVH filings page.
Evolent Health, Inc. (EVH) reported that its President, Daniel Joseph McCarthy, sold 65,892 shares of Class A Common Stock on August 26, 2026 at $5.00 per share in an open-market or private transaction. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on May 22, 2026. After this transaction, McCarthy directly holds 655,133 shares, which include previously granted restricted stock units.
Evolent Health, Inc. Chief Executive Officer Seth Blackley reported routine equity compensation and related tax withholding in Class A Common Stock. He received an award of 446,102 restricted stock units, granted at $0.00 per share under the Amended and Restated 2015 Omnibus Incentive Compensation Plan, with vesting scheduled at 34% on July 1, 2027 and 33% on July 1, 2028 and July 1, 2029. To cover tax obligations upon vesting of restricted stock units, 10,297 shares were withheld at an indicated value of $5.74 per share. Following these transactions, Blackley directly holds 1,272,767 shares of Class A Common Stock, including previously granted restricted stock units.
Evolent Health’s General Counsel Jonathan Weinberg received a grant of 43,055 restricted stock units of Class A Common Stock on July 1, 2026 under the Amended and Restated 2015 Omnibus Incentive Compensation Plan as part of the annual award cycle. On the same date, 2,650 shares were withheld to cover tax obligations upon vesting of previously granted RSUs. These RSUs vest 34% on July 1, 2027 and 33% on July 1, 2028 and July 1, 2029, and he now directly holds 284,917 shares of Class A Common Stock.
Evolent Health, Inc. president Daniel McCarthy reported equity compensation activity and related tax withholding. He received a grant of 302,585 restricted stock units of Class A Common Stock at no cost, approved by the Compensation Committee under the Amended and Restated 2015 Omnibus Incentive Compensation Plan. The award vests 34% on July 1, 2027, and 33% on July 1, 2028 and July 1, 2029. On the same date, 4,582 shares were withheld to cover tax obligations upon vesting of restricted stock units, a non-market disposition. After these transactions, McCarthy directly holds 721,025 shares of Class A Common Stock, including previously reported restricted stock units.
Shams Aammaad reported acquisition or exercise transactions in this Form 4 filing.
Evolent Health, Inc. reported that Chief Accounting Officer Shams Aammaad received a grant of 28,790 shares of Class A Common Stock in the form of restricted stock units under the Amended and Restated 2015 Omnibus Incentive Compensation Plan. These RSUs vest 34% on July 1, 2027 and 33% on July 1, 2028 and July 1, 2029. After this award, he holds 95,637 shares, including RSUs from prior grants.
Ajayi Toyin reported acquisition or exercise transactions in this Form 4 filing.
Evolent Health, Inc. reported that director Dr. Toyin Ajayi received an equity grant of 41,096 shares of Class A common stock in the form of restricted stock units under the company’s 2015 Omnibus Incentive Compensation Plan. After this award, Dr. Ajayi directly holds 75,170 shares. These restricted stock units vest on the earlier of June 4, 2027, or the date of Evolent Health’s 2027 annual meeting, assuming she continues to serve through the vesting date.
Glass Russell Monroe reported acquisition or exercise transactions in this Form 4 filing.
Evolent Health, Inc. director Russell Monroe Glass reported an equity award of 41,096 shares of Class A Common Stock in the form of restricted stock units granted at $0.00 per share under the company’s 2015 Omnibus Incentive Compensation Plan. These RSUs vest on the earlier of June 4, 2027 or the company’s 2027 annual meeting, subject to his continued service. Following the award, he directly owns 77,347 shares and indirectly holds 6,046 shares through a trust he and his spouse co‑trustee and over which they share voting and dispositive power.
GRUA PETER J reported acquisition or exercise transactions in this Form 4 filing.
Evolent Health, Inc. director Peter J. Grua reported a compensation-related equity grant rather than an open-market trade. He received 41,096 shares of Class A Common Stock in the form of restricted stock units at $0.00 per share under the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. These securities vest on the earlier of June 4, 2027 and the date of the company’s 2027 annual meeting, subject to his continued service. Following the grant, he directly holds 63,075 shares, and a trust for his sole benefit holds an additional 60,668 shares over which he has sole voting and dispositive power.
GUERTIN SHAWN M reported acquisition or exercise transactions in this Form 4 filing.
Evolent Health, Inc. director Shawn M. Guertin received an equity award of 41,096 shares of Class A Common Stock in the form of restricted stock units granted at no cash cost to him. These units were issued under the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.
The restricted stock units vest on the earlier of June 4, 2027, and the date of the company’s 2027 annual meeting, subject to his continued service through the vesting date. Following this award, Guertin directly holds 63,075 shares of Evolent Health Class A Common Stock.
Jelinek Richard M reported acquisition or exercise transactions in this Form 4 filing.
Evolent Health, Inc. director Richard M. Jelinek reported an equity award of Class A common stock. He received 41,096 restricted stock units at no purchase price under the company’s Amended and Restated 2015 Omnibus Incentive Compensation Plan. These units vest on the earlier of June 4, 2027, or the company’s 2027 annual meeting, if he continues serving through that date.
After the award, he holds 77,533 shares of Class A common stock directly, with additional 15,000-share positions shown in each of two trusts as indirect holdings.
KECK KIM reported acquisition or exercise transactions in this Form 4 filing.
Evolent Health director Kim Keck received an equity grant that increases her direct ownership stake. She was awarded 41,096 shares of Class A Common Stock in the form of restricted stock units under the company’s 2015 Omnibus Incentive Compensation Plan, bringing her direct holdings to 102,597 shares. These units vest on the earlier of June 4, 2027, or the company’s 2027 annual meeting, as long as she continues serving on the board.
Evolent Health, Inc. director Jill D. Smith reported an equity compensation grant. She acquired 41,096 shares of Class A Common Stock in the form of restricted stock units granted under the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.
The securities vest on the earlier of June 4, 2027 or the company’s 2027 annual meeting, contingent on her continued service through the vesting date. Following this award, Smith holds 64,233 shares of Evolent Health common stock directly.
Springstubb Brendan B reported acquisition or exercise transactions in this Form 4 filing.
Evolent Health, Inc. director Brendan B. Springstubb received a grant of 41,096 shares of Class A Common Stock in the form of restricted stock units at a price of $0.00 per share. Following this equity award, he holds 99,917 shares directly. The restricted stock units were granted under the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan and will vest on the earlier of June 4, 2027, or the company’s 2027 annual meeting, subject to his continued service.
Barbarosh Craig A. reported acquisition or exercise transactions in this Form 4 filing.
Evolent Health director Craig A. Barbarosh received an equity grant of 41,096 restricted stock units of Class A Common Stock. The award was made at no cash cost to him as part of Evolent Health’s 2015 Omnibus Incentive Compensation Plan. These units are scheduled to vest on the earlier of June 4, 2027, or the company’s 2027 annual meeting, contingent on his continued board service. Following this grant, he directly holds 95,031 shares of Class A Common Stock.
Evolent Health, Inc. CEO Seth Blackley reported equity award activity and related tax-withholding transactions. He received a grant of 1,425,310 performance-based share units at a price of $0.00 per unit and acquired 58,921 shares of Class A Common Stock upon settlement of earlier performance-based units.
To cover tax obligations tied to these vesting and settlement events, a total of 24,053, 17,736, and 9,537 shares of Class A Common Stock were withheld at per-share prices of $3.51, $3.58, and $3.25, respectively. After these transactions, Blackley directly owned 836,962 shares of Class A Common Stock and 1,425,310 performance-based share units, with the new PSUs eligible to be earned from March 1, 2027 to February 28, 2029 based on stock price and service conditions.
Evolent Health, Inc. General Counsel Jonathan Weinberg reported several equity compensation transactions involving the company’s Class A Common Stock and performance-based share units. On March 2, 2026, he received a grant of 179,661 performance-based share units at no cash cost and a separate award of 4,910 shares of Class A Common Stock.
On the same date, 1,896 shares were withheld at prices of $3.58 per share to cover tax obligations, and on March 1, 2026, an additional 4,406 shares were withheld at $3.25 per share for tax withholding. On March 3, 2026, a further 8,275 shares were withheld at $3.51 per share for tax liabilities. These “F” coded transactions reflect tax-withholding dispositions, not open-market sales, and left Weinberg with 244,512 shares of Class A Common Stock held directly.
Footnotes explain that some shares were delivered upon settlement of earlier performance-based awards after achievement of specified performance metrics, and the new PSUs may be earned between March 1, 2027 and February 28, 2029 based on stock price and service conditions, with potential payout from 0% to 250% of target.
Evolent Health president Daniel McCarthy reported a mix of equity grants and tax-related share withholdings. He received 826,440 performance-based share units at target under the company’s Amended and Restated 2015 Omnibus Incentive Compensation Plan, which may be earned based on specified stock price performance conditions from March 1, 2027 to February 28, 2029, subject to service conditions.
McCarthy also acquired 39,281 shares of Class A common stock upon settlement of a prior performance-based share unit award that vested at the end of 2025 after performance certification on March 2, 2026. To satisfy tax withholding obligations on vested restricted stock units and settled PSUs, 24,027, 18,192 and 7,811 Class A shares were withheld at prices between $3.25 and $3.58 per share. Following these transactions, he directly owned 423,022 Class A shares.
Evolent Health Chief Accounting Officer Shams Aammaad reported equity compensation activity and related tax withholding transactions. He received a grant of 55,173 performance-based share units (PSUs) and 1,686 shares of Class A Common Stock as awards. In separate moves, a total of 4,311, 850 and 2,577 Class A shares were withheld to cover tax obligations upon vesting and settlement of prior awards, described as tax-withholding dispositions rather than open-market sales. The new PSUs can be earned based on stock price performance conditions measured from March 1, 2027 to February 28, 2029, with potential payout from 0% to 250% of the target level, subject to service-based conditions.
Ramos Mario reported acquisition or exercise transactions in this Form 4 filing.
Evolent Health, Inc. Chief Financial Officer Mario Ramos received a grant of 429,041 performance-based share units (PSUs) at a price of $0.00 per unit. The PSUs are granted under the company’s Amended and Restated 2015 Omnibus Incentive Compensation Plan and may be earned based on stock price performance between March 1, 2027 and February 28, 2029, subject to service-based conditions. Each PSU is currently shown at a target level, and the final number earned can range from 0% to 250% of this target after the performance period.
Evolent Health, Inc. reported that director Ms. Smith received an equity award of 23,137 restricted stock units of Class A common stock on 01/02/2026. The units were granted at a price of $0 under the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan and are shown as directly owned after the transaction.
The restricted stock units vest on the earlier of January 2, 2027 or the date of the company’s 2026 annual meeting, as long as she continues in service through the vesting date.
Evolent Health, Inc. reported that its Chief Financial Officer received a special one-time restricted stock unit (RSU) grant. On 01/02/2026, the officer acquired 587,500 RSUs for Class A Common Stock at a price of $0 per unit, recorded as a direct holding. The grant was made as an employment inducement award under Rule 303A.08 of the New York Stock Exchange Listing Manual.
The RSUs vest over three years, with 34% scheduled to vest on January 2, 2027 and 33% on each of January 2, 2028 and January 2, 2029, subject to the executive’s continued employment through each vesting date. Upon vesting, each unit converts into one share of Class A Common Stock, aligning the CFO’s compensation more closely with the company’s equity performance.
Evolent Health, Inc. (EVH) reported an insider stock purchase by a director. On 11/18/2025, the director bought 10,000 shares of Class A common stock in an open-market transaction coded "P" at a price of $3.8199 per share. Following this trade, the director beneficially owns 58,821 shares, which include restricted stock units granted under prior awards. The filing is made by a single reporting person in the capacity of director and notes the potential use of a Rule 10b5-1 trading plan checkbox, although no selection detail is provided in this excerpt.